直接抗病毒药物对丙型肝炎治疗效果的影响因素

卞丹丹; 郑素军

doi:10.3969/j.issn.1001-5256.2017.11.034

直接抗病毒药物对丙型肝炎治疗效果的影响因素

DOI: 10.3969/j.issn.1001-5256.2017.11.034

首都医科大学附属北京佑安医院人工肝中心

基金项目:

基金项目:首都临床特色应用研究与成果推广(Z151100004015066)；

详细信息

中图分类号: R512.63
计量
- 文章访问数: 1816
- HTML全文浏览量: 12
- PDF下载量: 362
- 被引次数: 0
出版历程
- 收稿日期: 2017-05-25
- 出版日期: 2017-11-20

Influencing factors for the therapeutic effect of direct-acting antiviral agents in hepatitis C

Artificial Liver Treatment & Training Center, Beijing You An Hospital, Capital Medical University

Research funding:

摘要

摘要: 直接抗病毒药物的应用,显著提高了丙型肝炎患者的持续病毒学应答率,但仍有部分患者在治疗过程中出现不应答或者治疗后复发,其影响因素是目前研究的热点。从HCV耐药相关变异、HCV基因型、病毒载量的高低、肝脏病变程度以及合并用药等角度,综述了影响丙型肝炎直接抗病毒药物疗效的相关因素,以期对丙型肝炎的临床防治提供参考。
- 肝炎,丙型 /
- 抗病毒药 /
- 综述
Abstract: The application of direct-acting antiviral agents significantly increases the rate of sustained virologic response in patients with hepatitis C, but there are still some patients who have no response during treatment or experience recurrence after treatment.Related influencing factors are research hotspots at present.This article reviews the influencing factors for the therapeutic effect of direct-acting antiviral agents in hepatitis C from the perspectives of HCV resistance-related mutations, HCV genotypes, viral load, degree of liver lesions, and drug combination, in order to provide a reference for clinical prevention and treatment of chronic hepatitis C.
- hepatitis C /
- antiviral agents /
- review

HTML全文

参考文献(41)

[1]MOHD HANAFIAH K, GROEGER J, FLAXMAN AD, et al.Global epidemiology of hepatitis C virus infection:new estimates of age-specific antibody to HCV seroprevalence[J].Hepatology, 2013, 57 (4) :1333-1342.

[2]World Health Organization.Guidelines for the screening care and treatment of persons with chronic hepatitis C infection:updated version[EB/OL]. (2016-04) [2017-05-25]http://apps.who.int/iris/bitstream/10665/204452/1/WHO_HIV_2016.01_eng.pdf.

[3]EL-SERAG HB, RUDOLPH KL.Hepatocellular carcinoma:epidemiology and molecular carcinogenesis[J].Gastroenterology, 2007, 132 (7) :2557-2576.

[4]HUANG YW, YANG SS, FU SC, et al.Increased risk of cirrhosis and its decompensation in chronic hepatitis C patients with newonset diabetes:a nationwide cohort study[J].Hepatology, 2014, 60 (3) :807-814.

[5]BUNCHORNTAVAKUL C, MANEERATTANAPORN M, CHAVALIT-DHAMRONG D.Management of patients with hepatitis C infection and renal disease[J].World J Hepatol, 2015, 7 (2) :213-225.

[6]ASSELAH T, MARCELLIN P.Direct acting antivirals for the treatment of chronic hepatitis C:one pill a day for tomorrow[J].Liver Int, 2012, 32 (Suppl 1) :88-102.

[7]GE D, FELLAY J, THOMPSON AJ, et al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance[J].Nature, 2009, 461 (7262) :399-401.

[8]LAWITZ E, GANE EJ.Sofosbuvir for previously untreated chronic hepatitis C infection[J].N Engl J Med, 2013, 369 (7) :678-679.

[9]SHIFFMAN ML, SUTER F, BACON BR, et al.Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3[J].N Engl J Med, 2007, 357 (2) :124-134.

[10]SAXENA V, NYBERG L, PAULY M, et al.Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis[J].Hepatology, 2015, 62 (3) :715-725.

[11]BARTENSCHLAGER R, LOHMANN V.Replication of hepatitis Cvirus[J].J Gen Virol, 2000, 81 (Pt 7) :1631-1648.

[12]MANNS M, POL S, JACOBSON IM, et al.All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b:a multinational, phase 3, multicohort study[J].Lancet, 2014, 384 (9954) :1597-1605.

[13]Mc PHEE F, SUZUKI Y, TOYOTA J, et al.High sustained virologic response to daclatasvir plus asunaprevir in elderly and cirrhotic patients with hepatitis C virus genotype 1b without baseline NS5Apolymorphisms[J].Adv Ther, 2015, 32 (7) :637-649.

[14]ZEUZEM S, MIZOKAMI M, PIANKO S, et al.NS5A resistanceassociated substitutions in patients with genotype 1 hepatitis C virus:prevalence and effect on treatment outcome[J].J Hepatology, 2017, 66 (5) :910-918.

[15]LAWITZ E, MATUSOW G, DEJESUS E, et al.Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis:a phase 3 study (OPTIMIST-2) [J].Hepatology, 2016, 64 (2) :360-369.

[16]MANNS MP, Mc HUTCHISON JG, GORDON SC, et al.Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial[J].Lancet, 2001, 358 (9286) :958-965.

[17]ANDREONE P, COLOMBO MG, ENEJOSA JV, et al.ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97%and 100%sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection[J].Gastroenterology, 2014, 147 (2) :359-365, e1.

[18]FELD JJ, KOWDLEY KV, COAKLEY E, et al.Treatment of HCVwith ABT-450/r-ombitasvir and dasabuvir with ribavirin[J].NEngl J Med, 2014, 370 (17) :1594-1603.

[19]KOWDLEY KV, GORDON SC, REDDY KR, et al.Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis[J].N Engl J Med, 2014, 370 (20) :1879-1888.

[20]JACOBSON IM, GORDON SC, KOWDLEY KV, et al.Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options[J].N Engl J Med, 2013, 368 (20) :1867-1877.

[21]HULL MW, YOSHIDA EM, MONTANER JS.Update on current evidence for hepatitis C therapeutic options in HCV mono-infected patients[J].Curr Infect Dis Rep, 2016, 18 (7) :22.

[22]ZEUZEM S, DUSHEIKO GM, SALUPERE R, et al.Sofosbuvir and ribavirin in HCV genotypes 2 and 3[J].N Engl J Med, 2014, 370 (21) :1993-2001.

[23]NELSON DR, COOPER JN, LALEZARI JP, et al.All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection:ALLY-3 phase III study[J].Hepatology, 2015, 61 (4) :1127-1135.

[24]FELD JJ, JACOBSON IM, HEZODE C, et al.Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection[J].N Engl J Med, 2015, 373 (27) :2599-2607.

[25]FOSTER GR, AFDHAL N, ROBERTS SK, et al.Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection[J].N Engl J Med, 2015, 373 (27) :2608-2617.

[26]Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association.The guideline of prevention and treatment for hepatitis C:a 2015 update[J].J Clin Hepatol, 2015, 31 (12) :1961-1979. (in Chinese) 中华医学会肝病学分会, 中华医学会感染病学分会.丙型肝炎防治指南 (2015年更新版) [J].临床肝胆病杂志, 2015, 31 (12) :1961-1979.

[27]MAASOUMY B, MANNS MP.Optimal treatment with boceprevir for chronic HCV infection[J].Liver Int, 2013, 33 (Suppl 1) :14-22.

[28]JESUDIAN AB, JACOBSON IM.Optimal treatment with telaprevir for chronic HCV infection[J].Liver Int, 2013, 33 (Suppl 1) :3-13.

[29]MAASOUMY B, VERMEHREN J, WELKER MW, et al.Clinical value of on-treatment HCV RNA levels during different sofosbuvir-based antiviral regimens[J].J Hepatol, 2016, 65 (3) :473-482.

[30]ZHU Y, CHEN S.Antiviral treatment of hepatitis C virus infection and factors affecting efficacy[J].World J Gastroenterol, 2013, 19 (47) :8963-8973.

[31]SOFIA MJ.Nucleotide prodrugs for the treatment of HCV infection[J].Adv Pharmacol, 2013, 67:39-73.

[32]AL MARZOOQI SH, FELD JJ.Sorting out cirrhosis:mechanisms of non-response to hepatitis C therapy[J].Liver Int, 2015, 35 (8) :1923-1933.

[33]SCHOOLEY RT.The fragile relationship between hepatitis C virus and its human host[J].Top Antivir Med, 2014, 21 (5) :148-151.

[34]POORDAD F, HEZODE C, TRINH R, et al.ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis[J].N Engl J Med, 2014, 370 (21) :1973-1982.

[35]LAUFFENBURGER JC, MAYER CL, HAWKE RL, et al.Medication use and medical comorbidity in patients with chronic hepatitis C from a US commercial claims database:high utilization of drugs with interaction potential[J].Eur J Gastroenterol Hepatol, 2014, 26 (10) :1073-1082.

[36]KISER JJ, FLEXNER C.Direct-acting antiviral agents for hepatitis Cvirus infection[J].Annu Rev Pharmacol Toxicol, 2013, 53:427-449.

[37]KONDILI LA, GAETA GB, IELUZZI D, et al.Real-life data on potential drug-drug interactions in patients with chronic hepatitis Cviral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort Study[J].PLo S One, 2017, 12 (2) :e0172159.

[38]SORIANO V, LABARGA P, BARREIRO P, et al.Drug interactions with new hepatitis C oral drugs[J].Expert Opin Drug Metab Toxicol, 2015, 11 (3) :333-341.

[39]HUNDEMER GL, SISE ME, WISOCKY J, et al.Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency[J].Infect Dis (Lond) , 2015, 47 (12) :924-929.

[40]PETERSEN T, TOWNSEND K, GORDON LA, et al.High adherence to all-oral directly acting antiviral HCV therapy among an inner-city patient population in a phase 2a study[J].Hepatol Int, 2016, 10 (2) :310-319.

[41]WYLES D, POCKROS P, MORELLI G, et al.Ledipasvir-sofosbuvir plus ribavirin for patients with genotype 1 hepatitis C virus previously treated in clinical trials of sofosbuvir regimens[J].Hepatology, 2015, 61 (6) :1793-1797.

施引文献

资源附件(0)

访问统计